Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Symphony Clinical Research? Announces VP Appointment

Published: Thursday, February 21, 2013
Last Updated: Thursday, February 21, 2013
Bookmark and Share
Symphony Clinical Research? announced that industry veteran Kate Zarish has joined the company as its Vice President to lead and expand Global Clinical Operations.

Ms. Zarish is responsible for establishing and implementing the operational objectives and clinical processes employed by the global clinical team to deliver exceptional customer service with an unparalleled commitment to quality. She provides leadership to develop, grow and optimize the capabilities of Study Development, Study Management, Study Support and Document Management functions.

Ms. Zarish comes from Abbott Global Pharmaceutical Research & Development where she led an international team of study managers in the execution of clinical trial operations in multiple therapeutic areas. Kate was instrumental in the harmonization of global processes, tools and training programs for clinical study operations management, as well as standardizing study training for the monitoring staff. She maintains her certification as a Clinical Research Associate from ACRP.

“I am proud to be part of an organization that thinks about the patient first,” said Ms. Zarish. “The high standards we have established for in-home clinical services allows for trained health care professionals to ensure patient safety and to provide data with high integrity. It is the complete package for the patient, site and sponsor.”

Commenting on the new appointment, Nicki Norris, CEO states, “Kate’s role is critical in meeting the explosive demand for in-home clinical services. The pharmaceutical industry worldwide is beginning to realize the importance of reaching the intent-to-treat pool, accommodating debilitated patients, and retaining study participants all while completing trials on time. This is exactly what Symphony’s clinical services provide to our clients.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Alzheimer’s Treatment Moves a Step Closer
Merck scientists have reported the discovery of verubecestat, a structurally unique, orally bioavailable small molecule that has been shown to target the most visible sign of the disease in the brain.
Lynparza Phase III Progression-Free Survival Benefit
AstraZeneca announces results from Phase III SOLO-2 trial designed to determine the efficacy of Lynparza as a monotherapy for ovarian cancer.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!